Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].

0 avis

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].

Archive ouverte

Edité par CCSD ; Springer Verlag (Germany) [1976-....] -

International audience. Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer

Archive ouverte | Thureau, Sébastien | CCSD

International audience. Hypoxic areas are typically resistant to treatment. However, the fluorine-18-fluoroazomycin-arabinoside (FAZA) and fluorine 18 misonidazole (FMISO) tracers have never been compared in non sma...

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer

Archive ouverte | Mallet, Romain | CCSD

International audience. Sarcopenia is defined by a loss of skeletal muscle mass with or without loss of fat mass. Sarcopenia has been associated to reduced tolerance to treatment and worse prognosis in cancer patien...

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Archive ouverte | Thureau, Sébastien | CCSD

Chargement des enrichissements...

Syracuse